Alto Neuroscience ANRO Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Direct external program expenses: by Product | ||||||
| ALTO-100 | $1.76M+56.9% | $1.54M+171% | $1.71M-31.2% | $1.5M-29.1% | $1.12M-49.1% | |
| ALTO-101 | $5.36M+453% | $1.73M+1,719% | $1.39M+2.4% | $893K-5.2% | $969K+139% | |
| ALTO-203 | $6K-99.2% | $66K-94.2% | $218K-79.4% | $599K-30.8% | $737K+18.9% | |
| ALTO-207 | $4.14M— | $896K— | $345K— | $358K— | $0— | |
| ALTO-300 | $1.51M+63.4% | $1.5M-15.0% | $1.4M-29.8% | $653K-57.6% | $922K-17.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Alto Neuroscience break its business down?
- Alto Neuroscience (ANRO) reports direct external program expenses: by product across 5 parts — ALTO-100, ALTO-101, ALTO-203, ALTO-207 and ALTO-300. Each is extracted from the segment footnotes and tracked over time.
- Where does Alto Neuroscience's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Alto Neuroscience's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.